1h Free Analyst Time
Choroidal Neovascularization - Pipeline Review, H2 2019Speak directly to the analyst to clarify any post sales queries you may have.
Summary
The Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Choroidal Neovascularization - Pipeline Review, H2 2019, provides an overview of the Choroidal Neovascularization (Ophthalmology) pipeline landscape.
Choroidal neovascularization (CNV) involves the growth of new blood vessels that originate from the choroid Symptoms include painless loss of vision, metamorphopsia, and color disturbances. Treatment includes ant-VEGF agents, laser photocoagulation and photodynamic therapy.
Report Highlights
The Publisher's Pharmaceutical and Healthcare latest pipeline guide Choroidal Neovascularization - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Choroidal Neovascularization (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Choroidal Neovascularization (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Choroidal Neovascularization and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 1, 1, 9 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.
Choroidal Neovascularization (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from The Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Choroidal Neovascularization (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Choroidal Neovascularization (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Choroidal Neovascularization (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Choroidal Neovascularization (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Choroidal Neovascularization (Ophthalmology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Choroidal Neovascularization (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Choroidal Neovascularization (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
IntroductionReport Coverage
Choroidal Neovascularization - Overview
Choroidal Neovascularization - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Choroidal Neovascularization - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Choroidal Neovascularization - Companies Involved in Therapeutics Development
3SBio Inc
Allysta Pharmaceuticals Inc
AsclepiX Therapeutics Inc
F. Hoffmann-La Roche Ltd
Formycon AG
Iconic Therapeutics Inc
Isarna Therapeutics GmbH
Lupin Ltd
Mabion SA
NovelMed Therapeutics Inc
Oceanyx Pharmaceuticals Inc
Promedior Inc
Protheragen Inc
Yantai RC-Pharmaceutical Co Ltd
Choroidal Neovascularization - Drug Profiles
ACX-107 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Allo-Aca - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Oligonucleotides for Ophthalmology and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Apratoxin S4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
faricimab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Calreticulin for Choroidal Neovascularization - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ICON-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ISTH-0036 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit SCG3 for Metabolic Disorders, Oncology and Ophthalmology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit VEGF for Ophthalmology and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NM-9405 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRM-167 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ranibizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RC-28 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Choroidal Neovascularization and Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Choroidal Neovascularization - Dormant Projects
Choroidal Neovascularization - Discontinued Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Choroidal Neovascularization, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Choroidal Neovascularization - Pipeline by 3SBio Inc, H2 2019
Choroidal Neovascularization - Pipeline by Allysta Pharmaceuticals Inc, H2 2019
Choroidal Neovascularization - Pipeline by AsclepiX Therapeutics Inc, H2 2019
Choroidal Neovascularization - Pipeline by F. Hoffmann-La Roche Ltd, H2 2019
Choroidal Neovascularization - Pipeline by Formycon AG, H2 2019
Choroidal Neovascularization - Pipeline by Iconic Therapeutics Inc, H2 2019
Choroidal Neovascularization - Pipeline by Isarna Therapeutics GmbH, H2 2019
Choroidal Neovascularization - Pipeline by Lupin Ltd, H2 2019
Choroidal Neovascularization - Pipeline by Mabion SA, H2 2019
Choroidal Neovascularization - Pipeline by NovelMed Therapeutics Inc, H2 2019
Choroidal Neovascularization - Pipeline by Oceanyx Pharmaceuticals Inc, H2 2019
Choroidal Neovascularization - Pipeline by Promedior Inc, H2 2019
Choroidal Neovascularization - Pipeline by Protheragen Inc, H2 2019
Choroidal Neovascularization - Pipeline by Yantai RC-Pharmaceutical Co Ltd, H2 2019
Choroidal Neovascularization - Dormant Projects, H2 2019
Choroidal Neovascularization - Dormant Projects, H2 2019 (Contd..1), H2 2019
Choroidal Neovascularization - Discontinued Products, H2 2019
List of Figures
Number of Products under Development for Choroidal Neovascularization, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Targets, H2 2019
Number of Products by Stage and Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
Samples
LOADING...
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 3SBio Inc
- Allysta Pharmaceuticals Inc
- AsclepiX Therapeutics Inc
- F. Hoffmann-La Roche Ltd
- Formycon AG
- Iconic Therapeutics Inc
- Isarna Therapeutics GmbH
- Lupin Ltd
- Mabion SA
- NovelMed Therapeutics Inc
- Oceanyx Pharmaceuticals Inc
- Promedior Inc
- Protheragen Inc
- Yantai RC-Pharmaceutical Co Ltd
